Savara Announces Participation in Upcoming Healthcare Conferences
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, has announced its participation in two major healthcare conferences. The company will participate in fireside chats at the Jefferies London Healthcare Conference (November 19-21, 2024) and the Piper Sandler 36th Annual Healthcare Conference (December 3-5, 2024).
The fireside chats are scheduled for November 20th at 1:00pm GT/8:00am ET and December 3rd at 8:30am ET respectively. Live webcasts and replays will be accessible through Savara's corporate website and will remain available for 90 days.
Savara Inc. (Nasdaq: SVRA), una società biofarmaceutica in fase clinica specializzata in malattie rare delle vie respiratorie, ha annunciato la sua partecipazione a due importanti conferenze sanitarie. L'azienda parteciperà a conversazioni informali durante il Jefferies London Healthcare Conference (19-21 novembre 2024) e il Piper Sandler 36th Annual Healthcare Conference (3-5 dicembre 2024).
Le conversazioni sono programmate per il 20 novembre alle 13:00 GT/8:00 ET e il 3 dicembre alle 8:30 ET rispettivamente. I webcast dal vivo e le repliche saranno accessibili attraverso il sito web aziendale di Savara e rimarranno disponibili per 90 giorni.
Savara Inc. (Nasdaq: SVRA), una empresa biofarmacéutica en etapa clínica especializada en enfermedades raras respiratorias, ha anunciado su participación en dos conferencias importantes de salud. La compañía participará en charlas informales en la Jefferies London Healthcare Conference (19-21 de noviembre de 2024) y en la Piper Sandler 36th Annual Healthcare Conference (3-5 de diciembre de 2024).
Las charlas están programadas para el 20 de noviembre a la 1:00 PM GT/8:00 AM ET y el 3 de diciembre a las 8:30 AM ET respectivamente. Las transmisiones web en vivo y las repeticiones estarán accesibles a través del sitio web corporativo de Savara y estarán disponibles durante 90 días.
사바라 주식회사 (Nasdaq: SVRA)는 희귀 호흡기 질환 분야에서 임상 단계의 생명공학 회사로, 두 개의 주요 의료 회의에 참가한다고 발표했습니다. 이 회사는 제퍼리스 런던 헬스케어 컨퍼런스 (2024년 11월 19-21일)와 파이퍼 샌들러 제36회 연례 헬스케어 컨퍼런스 (2024년 12월 3-5일)에서 대담에 참여합니다.
대담은 각각 11월 20일 오후 1시 GT/오전 8시 ET와 12월 3일 오전 8시 30분 ET에 예정되어 있습니다. 라이브 웹캐스트와 재방송은 사바라의 기업 웹사이트를 통해 접근할 수 있으며, 90일간 이용 가능합니다.
Savara Inc. (Nasdaq: SVRA), une entreprise biopharmaceutique en phase clinique spécialisée dans les maladies respiratoires rares, a annoncé sa participation à deux importantes conférences sur la santé. L'entreprise participera à des discussions informelles lors de la Jefferies London Healthcare Conference (19-21 novembre 2024) et de la Piper Sandler 36th Annual Healthcare Conference (3-5 décembre 2024).
Les discussions sont prévues pour le 20 novembre à 13h00 GT/8h00 ET et le 3 décembre à 8h30 ET respectivement. Des webdiffusions en direct et des rediffusions seront accessibles via le site web de Savara et resteront disponibles pendant 90 jours.
Savara Inc. (Nasdaq: SVRA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf seltene Atemwegserkrankungen spezialisiert hat, hat seine Teilnahme an zwei wichtigen Gesundheitskonferenzen angekündigt. Das Unternehmen wird an informellen Gesprächen auf der Jefferies London Healthcare Conference (19.-21. November 2024) und der Piper Sandler 36. Jahrestagung zur Gesundheitspflege (3.-5. Dezember 2024) teilnehmen.
Die Gespräche sind für den 20. November um 13:00 Uhr GT/8:00 Uhr ET und für den 3. Dezember um 8:30 Uhr ET angesetzt. Live-Webcasts und Wiederholungen werden über die Unternehmenswebsite von Savara zugänglich sein und bleiben 90 Tage lang verfügbar.
- None.
- None.
Jefferies London Healthcare Conference, November 19-21, 2024
Fireside Chat: November 20th, 1:00pm GT/8:00am ET/5:00am PT
Piper Sandler 36th Annual Healthcare Conference, December 3-5, 2024
Fireside Chat: December 3rd, 8:30am ET/5:30am PT
The live webcasts and subsequent replays will be available on the “Events & Presentations” section of the Company’s corporate website at https://savarapharma.com/investors/events-presentations/ and will be archived for 90 days.
Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, MOLBREEVI*, is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed for inhalation of a large molecule. Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com, X: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name for molgramostim inhalation solution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241113397391/en/
Media and Investor Relations Contact
Savara Inc.
Temre Johnson, Executive Director, Corporate Affairs
ir@savarapharma.com
Source: Savara Inc.
FAQ
When is Savara (SVRA) presenting at the Jefferies London Healthcare Conference 2024?
What time is Savara's (SVRA) fireside chat at the Piper Sandler Healthcare Conference 2024?
How long will Savara's (SVRA) conference webcasts be available for viewing?
Where can I watch Savara's (SVRA) healthcare conference presentations?
